AWAnne P. Werner

Anne P. Werner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne P. Werner has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex differences in vaccine-induced neuraminidase cross-recognition and protection against H5N1 in mice

    by Sabal Chaulagain, Annie Werner, Maclaine A. Parish, Sattya Narayan Talukdar, Brittany A. Seibert, Tianle Zhang, Jennifer A. Liu, Cosette Schneider, Lynda Coughlan, Andrew Pekosz, et al.

    H5N1 vaccines have been poorly immunogenic in humans, creating a challenge for vaccine development. Seasonal influenza vaccines offer some cross-protection against H5N1, but there has been no consideration of whether protection differs between the sexes. We investigated antibody responses and protection in adult male and female C57BL/6 mice following vaccination with either beta-propiolactone inactivated whole virus H1N1 or H5N1 (LAIV backbone) vaccines. Using systems serology assays, we uncovered that vaccination induced strong homologous antibody responses, with females generating greater total IgG than males against both H1N1 and H5N1, which was primarily mediated by greater IgG responses to neuraminidase (NA) than hemagglutinin (HA) protein. Cross-reactive H1N1 IgG titers were greater among H5N1-vaccinated females, primarily mediated by greater N1-specific IgG titers. IgG2b and IgG2c were the primary antibody isotypes generated in response to these vaccines, with females having greater IgG2b titers and enhanced binding to FcγRIV for avian and human NA than males following either homologous or heterologous vaccination. Antibody-dependent complement deposition was measured as an FcR-mediated non-neutralizing response against HA and NA and was robust in both sexes. Vaccinated females had greater neutralizing antibody titers than males against the homologous vaccine strain, with limited cross-neutralizing antibodies detected in either sexes. Neuraminidase inhibition titers were greater in vaccinated females than males against the heterologous virus following H1N1 vaccination and against both the vaccine and heterologous viruses following H5N1 vaccination. When H1N1 and H5N1 vaccinated mice were challenged with a lethal dose of A/Texas/37/2024 H5N1, all H5N1 vaccinated mice were protected, regardless of sex. Among H1N1 vaccinated mice, while both sexes were protected against disease, H1N1 vaccinated females cleared virus faster than their male counterparts. These findings highlight that female-biased NA-specific antibodies result in greater cross-protection and should be considered in studies of influenza vaccines. Highlights: Females mount stronger IgG responses than males to both H1N1 and H5N1 vaccines Sex differences in vaccine responses are driven by immunity to neuraminidase (NA) Females mount stronger anti-NA IgG2b responses with greater binding to FcγRIV than males NA inhibition titers are greater in females, supporting broader cross-protection H1N1-vaccinated females clear H5N1virus faster than males after lethal challenge

  • Open Access

    Genomic Evolution of Influenza A Virus During the 2024–2025 Season, the Johns Hopkins Health System: Antigenic Drift Reduces Serum Neutralization

    by David Villafuerte, Amary Fall, Elgin Akin, Anne P Werner, Matthew Pinsley, Yee Vue, Omar Abdullah, Ting Xuan Zhuang, Julie M Norton, Richard E Rothman, et al.

    Background: Seasonal influenza causes significant global morbidity, mortality, and economic burden. Ongoing viral evolution can lead to vaccine mismatch and the emergence of antiviral resistance, highlighting the importance of genomic surveillance. The 2024–2025 influenza season was characterized by high incidence and increased hospitalizations. Methods: We analyzed influenza A virus (IAV) genomes and clinical characteristics from the 2024–2025 season. Whole-genome sequencing was performed on 648 influenza A–positive clinical specimens collected between October 2024 and April 2025. Results: Hemagglutinin (HA) sequences were recovered from 74.23% (481/648) of samples and used for subtyping and phylogenetic analysis. A(H1N1)pdm09 and A(H3N2) viruses cocirculated, representing 55.5% and 44.5% of cases, respectively. Among A(H1N1)pdm09 viruses, the HA1 substitution T120A, located near the Sa antigenic site, increased more than 2-fold compared with the prior season. Circulating A(H3N2) viruses belonged to multiple HA subclades and exhibited distinct amino acid substitutions at key antigenic sites. Neutralization assays using sera from individuals vaccinated with the 2024–2025 seasonal influenza vaccine demonstrated reduced neutralization of 3 dominant A(H1N1)pdm09 isolates and 2 A(H3N2) isolates compared with vaccine strains, consistent with antigenic drift. In addition, the neuraminidase substitution S247N, previously associated with reduced oseltamivir susceptibility, was detected in 13.9% of A(H1N1)pdm09 samples. Conclusions: These findings demonstrate ongoing antigenic drift and the presence of antiviral resistance–associated mutations during the 2024–2025 influenza season, underscoring the need for continued genomic surveillance to guide vaccine and antiviral strategies.


  • Open Access

    Low levels of influenza H5N1 HA and NA antibodies in the human population are boosted by seasonal H1N1 infection but not by H3N2 infection or influenza vaccination

    by Anne P. Werner, Cosette G. Schneider, Elgin H. Akin, Juliahna Hayes, Katherine Z. J. Fenstermacher, Richard E. Rothman, Lynda Coughlan, Andrew Pekosz

    An increase in the number of human cases of influenza A/H5N1 infection in the USA has raised concerns about the pandemic potential of the virus. Pre-existing population immunity is a key determinant for risk assessment and pandemic potential for any virus. Antibody responses against the bovine A/H5N1 hemagglutinin (HA) and neuraminidase (NA) proteins were measured among a population of influenza-vaccinated or influenza-infected individuals. Modest titers of bovine A/H5N1 HA-binding antibodies and low to undetectable neutralizing antibody titers were detected in a cohort of 73 individuals. Conversely, bovine A/H5N1 NA-binding and neuraminidase-inhibiting antibody titers were comparable to those against a human A/H1N1 NA at baseline. Seasonal influenza vaccination failed to significantly increase antibody titers against both HA and NA glycoproteins of bovine A/H5N1. Recent infection with human A/H1N1 but not A/H3N2 viruses induced significant increases in bovine A/H5N1-neutralizing antibody, as well as increases in NA-binding and NA-inhibiting antibodies to bovine A/H5N1 NA. While the degree of protection afforded by these A/H5N1 cross-reactive antibodies is not known, incorporating NA or enhancing current seasonal vaccine formulations to increase NA-specific antibody titers may increase antibody breadth and protection against both seasonal and pandemic influenza viruses. IMPORTANCE: A/H5N1 influenza A viruses continue to pose a pandemic threat to humans. Recent infection of dairy cattle and poultry with A/H5N1 in the USA has magnified that concern. We determined the level of antibodies that recognize A/H5N1 hemagglutinin (HA) and neuraminidase (NA) proteins in a population in Baltimore, MD. We show that while low levels of H5 HA-binding and A/H5N1-neutralizing antibodies are present, there is a significantly stronger recognition of bovine N1 NA. Vaccines that target the N1 NA protein may induce protective antibody responses in humans due to the presence of cross-reactive human N1 NA antibodies.


  • Open Access

    Stabilized coronavirus spike stem elicits a broadly protective antibody

    by Ching-Lin Hsieh, Anne P. Werner, Sarah R. Leist, Laura J. Stevens, Ester Falconer, Jory A. Goldsmith, Chia-Wei Chou, Olubukola M. Abiona, Ande West, Kathryn Westendorf, et al.


  • mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

    by Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagne, Lilin Lai, Juan I. Moliva, Barbara Flynn, Angela Choi, Matthew Koch, Kathryn E. Foulds, et al.

    B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 µg of Moderna’s mRNA-1273 vaccine, a single immunization of 30 µg, or no vaccine. Two doses of 100 µg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log10 reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log10 reduction in nasal swabs in the 100-µg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.


  • Top Cited Papers

    Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

    by Kai Wu, Anne P. Werner, Matthew Koch, Angela Choi, Elisabeth Narayanan, Guillaume B.E. Stewart-Jones, Tonya Colpitts, Hamilton Bennett, Seyhan Boyoglu-Barnum, Wei Shi, et al.

    The mRNA-1273 vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited high neutralizing-antibody titers in phase 1 trial participants1,2 and has been shown to be highly efficacious in preventing symptomatic Covid-19 disease and severe disease.3 The emergence of SARS-CoV-2 variants in the United Kingdom (the B.1.1.7 lineage), South Africa (the B.1.351 lineage), Brazil (the P.1 lineage), and California (the B.1.427/B.1.429 lineage) has led to concerns about increased transmission and the potential of these variants to circumvent immunity elicited by natural infection or vaccination. The recent identification in the United Kingdom of a B.1.1.7 variant that includes the E484K mutation (B.1.1.7+E484K) furthers these concerns.


  • Open Access

    Hierarchical routing in carbon metabolism favors iron-scavenging strategy in iron-deficient soil Pseudomonas species

    by Caroll M. Mendonca, Sho Yoshitake, Hua Wei, Anne Werner, Samantha S. Sasnow, Theodore W. Thannhauser, Ludmilla Aristilde

    Significance: Siderophore secretion confers competitive advantage to pathogenic and beneficial bacteria in various nutritional environments, including human infections and rhizosphere microbiome. The siderophore biosynthesis must be sustained during a compromised carbon metabolism in Fe-deficient cells. Here we demonstrate that Fe-deficient Pseudomonas species overcome this paradox by coupling selectivity in carbon utilization with a hierarchy in metabolic pathways to favor carbon and energy fluxes for siderophore biosynthesis. A reprogrammed metabolism is predicted from genomics-based data obtained with several marine and soil bacterial systems in response to Fe deficiency, but metabolomics evidence is lacking. The present study offers an important roadmap for investigating the underlying metabolic connections between Fe or other metal nutrient availability and carbon utilization.